About This Research Desk

What Aus Peptide is

Aus Peptide is an independent editorial reference desk covering the published research behind three peptides discussed under the loose banner of the growth hormone (GH) axis: CJC-1295/Ipamorelin, MOTS-c, and sermorelin, with sermorelin as the lead compound because it carries by far the deepest clinical trial record of the three. The desk's organizing frame is GHRH and GHRP research peptides, side by side — a deliberately narrow lens that groups two GHRH-receptor-facing compounds (sermorelin, and the CJC-1295 half of the combination) with one ghrelin-receptor-facing compound (ipamorelin) and, honestly, one outlier that doesn't fit the frame mechanistically at all (MOTS-c).

That outlier is included on purpose, not by accident. Research-use communities interested in GH-axis peptides for sleep, recovery, and body composition very often research MOTS-c in the same breath, even though its actual biology — mitochondrial signaling and AMPK/CK2 activation — has nothing to do with the pituitary. This site treats that honestly: each compound page states plainly what a peptide's mechanism actually is, rather than forcing every entry into a tidy shared narrative for the sake of a clean category page.

How it is compiled

Three editorial principles govern everything on this site.

First, every research claim is tied to a citation. Peer-reviewed journal articles, clinical trial reports, and authoritative reviews are collected, numbered, and linked with DOIs and PubMed identifiers on the references page; a claim without a number behind it is either general background or explicitly framed as an anecdotal community report.

Second, the evidence is described at the strength it was actually generated with. A single-dose pharmacokinetic study in healthy adults is not described the same way as a randomized, placebo-controlled trial in a clinical population, and a mouse study is never quietly presented as if it were a human result. Where a combination product like CJC-1295/Ipamorelin has never itself been tested, this site says so directly rather than blending single-agent data into an implied combination result.

Third, community-reported effects are labeled as exactly that. Where research-use communities describe benefits or side effects that have not been measured in a controlled study, this site presents them clearly as anecdotal — useful context, not evidence, and never a basis for a recommended dose.

What it is not

Aus Peptide is not a pharmacy, a clinic, a telehealth platform, or a peptide vendor. It does not sell, source, or broker any compound discussed here, and it has no referral or affiliate relationship with any supplier, clinic, or manufacturer. It does not diagnose, prescribe, or recommend a dose, schedule, or route of administration for any individual, and nothing on this site should be read as a substitute for care from a licensed clinician.

Sermorelin is available through compounding pharmacies under a licensed prescriber's direction; CJC-1295, ipamorelin, and MOTS-c are, as of this writing, sold only as research chemicals with no approved human indication. Readers seeking clinical guidance about growth-hormone-axis concerns should consult a licensed healthcare provider. Editorial correspondence — a citation correction, a newly published trial, a regulatory update — can be directed to the contact page; this desk reads that correspondence carefully and cannot respond to requests for medical advice.